Subjective well-being and quality of life under atypical antipsychotic treatment

[1]  H. Rüdiger,et al.  Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs , 2001, Schizophrenia Research.

[2]  Z. Cernovsky,et al.  Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life , 2000, Schizophrenia Research.

[3]  S. Browne.  Rehabilitation Programmes and Quality of Life in Severe Mental Illness , 1999, The International journal of social psychiatry.

[4]  N. Andreasen,et al.  A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. , 1999, The Journal of clinical psychiatry.

[5]  D. Revicki,et al.  Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial , 1999, Quality of Life Research.

[6]  A. Rush,et al.  Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center. , 1999, Clinical therapeutics.

[7]  Alexander L. Miller,et al.  Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization , 1999, Psychiatry Research.

[8]  G. Tollefson,et al.  Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? , 1999, The Journal of clinical psychiatry.

[9]  D. Revicki.  Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia , 1999, Schizophrenia Research.

[10]  J. Gibert,et al.  Quality of life in schizophrenia: Long-term follow-up in 362 chronic Spanish schizophrenic outpatients undergoing risperidone maintenance treatment , 1998, European Psychiatry.

[11]  J. Arnt.  Pharmacological differentation of classical and novel antipsychotics , 1998, International clinical psychopharmacology.

[12]  M. Roe,et al.  Quality of life in schizophrenia: insight and subjective response to neuroleptics. , 1998, The Journal of nervous and mental disease.

[13]  R. Heslegrave,et al.  Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability , 1998, Psychological Medicine.

[14]  G. Tollefson,et al.  Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. , 1997 .

[15]  C. Pariante,et al.  Symptoms, standards of living and subjective quality of life: a comparative study of schizophrenic and depressed out‐patients , 1997, Acta psychiatrica Scandinavica.

[16]  R. Rosenheck,et al.  A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. , 1997, The New England journal of medicine.

[17]  A. Awad,et al.  Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. The Canadian Remoxipride Group. , 1997, Journal of psychiatry & neuroscience : JPN.

[18]  B. Gallhofer,et al.  Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients , 1997, British Journal of Psychiatry.

[19]  R. Tamura,et al.  Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. , 1997, The American journal of psychiatry.

[20]  J. Gerlach,et al.  Subjective experience of treatment, side‐effects, mental state and quality of life in chronic schizophrenic out‐patients treated with depot neuroleptics , 1996, Acta psychiatrica Scandinavica.

[21]  F. Sainfort,et al.  Judgments of quality of life of individuals with severe mental disorders: Patient self-report versus provider perspectives. , 1996, The American journal of psychiatry.

[22]  D. Naber.  A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables , 1995, International clinical psychopharmacology.

[23]  D. Casey.  Motor and mental aspects of extrapyramidal syndromes , 1995, International clinical psychopharmacology.

[24]  T M Gill,et al.  A critical appraisal of the quality of quality-of-life measurements. , 1994, JAMA.

[25]  T. Lewander.  Neuroleptics and the neuroleptic‐induced deficit syndrome , 1994, Acta psychiatrica Scandinavica. Supplementum.

[26]  N. Schooler.  Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic‐induced deficits , 1994, Acta psychiatrica Scandinavica. Supplementum.

[27]  T. Hogan,et al.  Subjective response to neuroleptics and the quality of life: implications for treatment outcome , 1994, Acta psychiatrica Scandinavica. Supplementum.

[28]  U. Malm,et al.  Comparison of Quality of Life with Standard of Living in Schizophrenic Out-patients , 1992, British Journal of Psychiatry.

[29]  T. Hogan,et al.  Measurement of therapeutic response in schizophrenia A critical survey , 1991, Schizophrenia Research.

[30]  J. Hasford,et al.  Evaluating quality-of-life measures for clinical trials in Germany. , 1991, Controlled clinical trials.

[31]  H. Meltzer,et al.  Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. , 1990, Hospital & community psychiatry.

[32]  A. Lehman.  The well-being of chronic mental patients. , 1983, Archives of general psychiatry.

[33]  T. Hogan,et al.  A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity , 1983, Psychological Medicine.

[34]  M. Bergner,et al.  The Sickness Impact Profile: Development and Final Revision of a Health Status Measure , 1981, Medical care.

[35]  S. Marder,et al.  Subjective response to antipsychotic drugs. , 1981, Archives of general psychiatry.

[36]  R. A. May,et al.  Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. , 1978, Archives of general psychiatry.

[37]  B. Gallhofer,et al.  The importance of social comparisons for high levels of subjective quality of life in chronic schizophrenic patients , 2004, Quality of Life Research.

[38]  R. Heslegrave,et al.  A conceptual model of quality of life in schizophrenia: Description and preliminary clinical validation , 2004, Quality of Life Research.

[39]  W. Rein,et al.  Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. , 2000, International clinical psychopharmacology.

[40]  D. Revicki,et al.  Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial. , 1999, PharmacoEconomics.

[41]  W S Fenton,et al.  Determinants of medication compliance in schizophrenia: empirical and clinical findings. , 1997, Schizophrenia bulletin.

[42]  M. Atkinson,et al.  Characterizing quality of life among patients with chronic mental illness: a critical examination of the self-report methodology. , 1997, The American journal of psychiatry.

[43]  M. Bullinger.  Generic quality of life assessment in psychiatry. Potentials and limitations , 1997, European Psychiatry.

[44]  A. Awad.  Subjective response to neuroleptics in schizophrenia. , 1993, Schizophrenia bulletin.

[45]  Ware J.E.Jr.,et al.  THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .

[46]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[47]  W T Carpenter,et al.  The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. , 1984, Schizophrenia bulletin.

[48]  U. Malm,et al.  Evaluation of the quality of life of the schizophrenic outpatient: a checklist. , 1981, Schizophrenia bulletin.